oral glp-1 US FDA accepts Novo Nordisk's application for Wegovy for weight loss Eli Lilly's oral GLP-1 pill

These may include: Nausea, vomiting or diarrhoea (most common early on) Constipation Fatigue Mild increases in heart rate (similar to changes seen with GLP-1 medicines) Side effects were more frequent at higher doses (8 mg and 12 mg), but still rated mild to moderate overall

Q

S.IbrahimR

In the STEP-4 trial, 902 participants received semaglutide 2.4 mg for the initial 20 weeks, and were then randomly assigned to receive either (a) semaglutide or (b) a placebo for the remaining 48 weeks (4)

Which of those drugs have existing Paragraph IV challenges filed, and by whom

As per FMI estimates, these two leaders collectively control a significant majority of market value, particularly in premium diabetes and obesity segments